Shorter radiation for prostate cancer recurrence? new trial tests 2-Week option

NCT ID NCT07500701

Recruiting now Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial compares two types of radiation therapy for men whose prostate cancer has returned after surgery. One schedule takes 5-6 weeks, while the other is completed in just 2 weeks. The study aims to see if the shorter option works just as well with manageable side effects, potentially making treatment more convenient and less costly. It involves 270 participants across multiple centers in South Korea.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiotherapy (ultra-hypofractionated vs. moderate hypofractionated)
What this could lead to: If successful, this could offer a shorter, more convenient radiotherapy option for men with prostate cancer recurrence after surgery, reducing treatment time from weeks to just two weeks.
What could go wrong: This is an early-stage comparison in a specific group of patients, and the shorter schedule may not be as effective or could cause different side effects. Results may not apply to all prostate cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Samsung Medical Center
RECRUITING

Seoul, Gangnam-gu, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.